Status:
COMPLETED
Low Level Laser Therapy to Reduce Pain After Breast Augmentation Surgery
Lead Sponsor:
Erchonia Corporation
Conditions:
Pain
Eligibility:
FEMALE
18-55 years
Phase:
NA
Brief Summary
The goal of the clinical study was to see if applying low level laser light therapy to the breasts during breast implant surgery could lessen pain experienced by 24 hours after the surgery.
Detailed Description
Substantial pain, discomfort and swelling following breast augmentation surgery is not uncommon. The ability of low level laser therapy to reduce swelling and inflammation that subsequently reduces pa...
Eligibility Criteria
Inclusion
- Suitability for breast augmentation surgery based on the need for correction of a congenital deformity or condition such as: Amastia, Hypomastia, Hypoplasia, Pectus Carinatum, Pectus Excavatum, OR a cosmetic breast enhancement indication, including: Augmentation to increase breast size, correction of ptotic (drooping) or pendulous (sagging) breasts, recontouring to obtain enhanced breast shape.
- Bilateral breast augmentation indication only.
- 18 to 55 years, inclusive.
- Female, only.
- Willingness, and ability, to refrain from consuming over-the-counter and/or prescription medications for the indication of the relief of pain and/or swelling, including any non-steroidal anit-inflammatory drugs (NSAIDs), from 48 hours immediately prior to the laser-assisted breast implant procedure through to one week post-procedure.
Exclusion
- Breast augmentation procedures indicated for the purpose of breast reconstruction following mastectomy or an injury due to severe trauma.
- Presence of a specific connective tissue disorder.
- Inadequate tissue available to cover the implants.
- Consumption of any one or more of narcotics, opiates, and/or steroids.
- Inability to consume the following medications post-operatively due to allergy, intolerance, or any other reason:
- (i) Pain medication for the relief of post-operative pain of Lortab 10/500 or another drug within the combination narcotic analgesic drug category within which Lortab falls.
- (ii) Antibiotic medication for reducing the risk of post-operative infection of Keflex 500 mg or Cipro 500 mg or another drug within the broad-spectrum antibiotic drug category within which Keflex and Cipro fall.
- Developmental disability or cognitive impairment that impacts a subject's ability to read and/or to understand the content of the informed consent form, and/or impacts a subject's ability to read and /or to understand and/or to complete the required case report form information for the clinical study.
- Significant psychological disorder(s) for which treatment has become necessary, including anxiety and depression; psychiatric hospitalization.
- Pregnancy or lactation.
- Prior surgery to the breast area, or to the area of the intended incision.
- Infection or wound in the intended areas of treatment.
- Involvement in litigation and/or receiving disability benefits related to the subject's breast(s).
- Participation in research over the preceding 90 days.
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT00926887
Start Date
September 1 2005
End Date
July 1 2007
Last Update
April 17 2014
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.